Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, HIF-1α (but not HIF-2α) has also been shown to enhance the self-renewal activity of stem-like U251 and U87 GBM cells and to inhibit the induction of differentiation suggesting that the HIF-α isoform dependency involved in the hypoxia-mediated maintenance of GBM stem-like cells may be cell type specific [50–52].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
RETRACTED: Collagen Prolyl Hydroxylases Are Essential for Breast Cancer Metastasis
Gilkes, D. M., Chaturvedi, P., Bajpai, S., Wong, C. C., Wei, H., Pitcairn, S., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3963 · Cited by 296
RetractedProcollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis
Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0629 · Cited by 252
RetractedGilkes, D. M., Xiang, L., Lee, S. J., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321510111 · Cited by 184
RetractedPonnala, S., Veeravalli, K. K., Chetty, C., Dinh, D. H., & Rao, J. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026191 · Cited by 24
RetractedWang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Research works printed but not linked: 2
- 10.1128/mcb.12.12.5447-5454.1992 · doi:10.1128/mcb.12.12.5447-5454.1992 · Paper page
- Wallace E . PT2385: HIF-2a antagonist for the treatment of VHL mutant ccRCC. Proceedings of : 12th International VHL Medical Symposium. MA, USA, 7–9 April 2016 .
Cited by
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Targeting Glioblastoma Stem Cells: A Review on Biomarkers, Signal Pathways and Targeted Therapy
Tang, X., Zuo, C., Fang, P., Liu, G., Qiu, Y., Huang, Y., & Tang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701291 · Cited by 140
Yin, J., Ge, X. Q., Shi, Z., Chen, Y., Lu, C., Wei, Y., Zeng, A., Wang, X., Yan, W., Zhang, J., et al. (2020) · Theranostics · doi:10.7150/thno.47057 · Cited by 113
Hypoxia-mediated cancer stem cell resistance and targeted therapy
Sun, X., Lv, X., Yan, Y., Zhao, Y., Ma, R., He, M., & Wei, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110623 · Cited by 99
Renfrow, J. J., Soike, M. H., West, J. L., Ramkissoon, S. H., Metheny-Barlow, L., Mott, R. T., Kittel, C. A., D’Agostino, R. B., Tatter, S. B., Laxton, A. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72290-2 · Cited by 45
Self-citationWang, P., Yan, Q., Liao, B., Zhao, L., Xiong, S., Wang, J., Zou, D., Pan, J., Wu, L., Deng, Y., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03150-0 · Cited by 60
Strowd, R., Ellingson, B., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M., Piotrowski, A., Desai, A., Clarke, J. L., Lieberman, F. S., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04456-7 · Cited by 36
“Preclinical studies have demonstrated signal-agent activity in patient-derived in vitro and in vivo models of glioma [35, 36].”
BackgroundBegagić, E., Bečulić, H., Džidić-Krivić, A., Vukas, S. K., Hadžić, S., Mekić–Abazović, A., Šegalo, S., Papić, E., Muchai, E., Pugonja, R., et al. (2024) · Cancers · doi:10.3390/cancers16112089 · Cited by 36
“Biomarkers such as isocitrate dehydrogenase (IDH) mutations and O6-methylguanine DNA methyltransferase (MGMT) methylation status support prognosis [5].”
BackgroundMacklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 35
“in maintenance of glioblastoma multiforme (GBM) stem cells [215] and its inhibition has been proposed to be a credible therapeutic approach in this tumour type [216].”
BackgroundGene silencing of HIF-2α disrupts glioblastoma stem cell phenotype
Nusblat, L. M., Tanna, S., & Roth, C. M. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.96 · Cited by 35
The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology
Libby, C. J., McConathy, J., Darley-Usmar, V. M., & Hjelmeland, A. B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1169 · Cited by 26
Oxygen Sensing and Viral Replication: Implications for Tropism and Pathogenesis
Liu, P. J., Balfe, P., McKeating, J. A., & Schilling, M. (2020) · Viruses · doi:10.3390/v12111213 · Cited by 25
Crake, R., Burgess, E. R., Royds, J. A., Phillips, E., Vissers, M. C. M., & Dachs, G. U. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.619300 · Cited by 25
Transcription Factors with Targeting Potential in Gliomas
Giannopoulou, A.-I., Kanakoglou, D. S., & Piperi, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073720 · Cited by 25
“HIF-2α expression has been linked to transmembrane CD44 glycoprotein produced by stem cells in the perivascular niche of GBMs. Functional studies, employing knockdown of the factor in GSCs, demonstrated decreased tumor sphere formation, reduced GSC-mediated angiogenesis (in vitro), induction of cell apoptosis, and rep…”
BackgroundInfluentialMicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma
Yazdi, M. P., Barjasteh, A., & Moghbeli, M. (2024) · Molecular Brain · doi:10.1186/s13041-024-01113-6 · Cited by 30
“Critical cellular responses to hypoxia include the stability and activation of HIF1α and HIF2α that have a vital role in tumor progression [165, 166].”
BackgroundEspinoza, F. I., Tankov, S., Chliate, S., Couto, J. P., Marinari, E., Vermeil, T., Lecoultre, M., Harane, N. E., Dutoit, V., Migliorini, D., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05642-8 · Cited by 27
“HIF-2α targeting is clinically efficacious in certain solid tumors, with early studies suggesting promise for GBM [41 , 46 ].”
Xu, L., Xie, X., & Luo, Y. (2021) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2021.151153 · Cited by 21
Notch intracellular domain regulates glioblastoma proliferation through the Notch1 signaling pathway
Wang, Y., Sun, Q., Geng, R., Liu, H., Yuan, F., Xu, Y., Qi, Y., Jiang, H., Chen, Q., & Liu, B. (2021) · Oncology Letters · doi:10.3892/ol.2021.12564 · Cited by 20
Wang, P., Gong, S., Liao, B., Liu, J., Zhao, L., & Wu, N. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03823-w · Cited by 18
“HIF-1α and HIF-2α have been demonstrated to contribute substantially to the malignant progression of GBM, with redundant and unique regulatory functions under hypoxic conditions [5, 29, 31].”
Toussaint, M., Deuther‐Conrad, W., Kranz, M., Fischer, S., Ludwig, F., Juratli, T. A., Patt, M., Wünsch, B., Schackert, G., Sabri, O., et al. (2020) · Molecules · doi:10.3390/molecules25092170 · Cited by 13
The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia
Magliulo, D., Simoni, M., Caserta, C., Fracassi, C., Belluschi, S., Giannetti, K., Pini, R., Zapparoli, E., Beretta, S., Uggé, M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317810 · Cited by 12
“Source data are available online for this figure.”
BackgroundMethodInfluentialWaseem, A., Rashid, S., Rashid, K., Khan, M. A., Khan, R., Haque, R., Seth, P., & Raza, S. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.006 · Cited by 8
Hsiao, H., Lu, G., Liu, Y., & Wu, S. (2021) · Membranes · doi:10.3390/membranes11080636 · Cited by 7
“Moreover, some researchers have performed studies to demonstrate the effectiveness of this compound in suppressing the growth and invasiveness of gliomas [18,19].”
BackgroundMoyama, C., Fujita, M., Ando, S., Taniguchi, K., Ii, H., Tanigawa, S., Hashimoto, N., & Nakata, S. (2022) · PubMed Central · Cited by 9
The Critical Role of RNA m6A Methylation in Gliomas: Targeting the Hallmarks of Cancer
Xu, Z., Jiang, J., & Wang, S. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01283-8 · Cited by 7
Khakshour, E., Bahreyni-Toossi, M.-T., Anvari, K., Shahram, M. A., Vaziri-Nezamdoust, F., & Azimian, H. (2023) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2023.111848 · Cited by 9
The clinical landscape of HIF2α inhibitors in oncology
Saad, E., Machaalani, M., McDermott, D. F., & Choueiri, T. K. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01145-y · Cited by 6
“HIF2α is frequently overexpressed in glioblastoma, particularly in high-grade tumours and glioma stem cells within hypoxic perivascular and perinecrotic regions, and correlates with poor patient outcomes 173,174 .”
A coregulatory influence map of glioblastoma heterogeneity and plasticity
Bernhard, C., Geles, K., Pawlak, G., Dhifli, W., Dispot, A., Dusol, J., Kondratova, M., Martin, S., Messé, M., Reita, D., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00890-0 · Cited by 6
“In addition, our co-regulated subnetwork for MES tumors con fi rmed the established role of the hypoxic tumor micro-environment, as suggested by the inclusion of EPAS1 and CEBPD , both master TFs for hypoxia-regulated genes in GBM 46,47 .”
Von Hippel–Lindau/Hypoxia Inducible Factor Axis in Glioblastoma
Flores, I., Salazar, A., de la Cruz, V. P., Mena-Guerrero, T., Cossio, J. Á. N., Figueroa, R., Cancino-Diaz, M. E., & Pineda, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209979 · Cited by 3
“HIF-2 α promotes the expression of Nestin and CD133, markers of glioma stemness [62,63].”
Elmaogod, E. A. A., Daoud, S. A., Mostafa, Z. M., & Mahmoud, E. M. M. (2022) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-022-00325-w · Cited by 2
“HIF-1α down regulation could increase the effect of gliomas therapy by cell cycle and apoptosis mechanisms modulation [4, 5].”
BackgroundHypoxia and Regulation of Cancer Cell Stemness
Ray, S. K., & Mukherjee, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1016-7_8 · Cited by 2
Han, D., Weitz, I. S., Slika, H., Tyler, B., & Steckl, A. J. (2025) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500124 · Cited by 1
Bhatt, L. K., Gokani, S., & Barve, K. H. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-1247-3_90-1 · Cited by 1
Bhatt, L. K., Gokani, S., & Barve, K. H. (2022) · Handbook of Oxidative Stress in Cancer: Therapeutic Aspects · doi:10.1007/978-981-16-5422-0_90 · Cited by 1
(2020) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22585
RetractedHIF-2α Interaction with Ataxin-10 Enhances HIF-2α Binding to Its Target Gene Promoters
Diseri, A., Gkotinakou, I., Befani, C. D., Pappas, I. S., Samiotaki, M. K., Panayotou, G., & Liakos, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110417 · Cited by 1
Rôle et ciblage de HIF-2a dans les gliomes de haut-grade pédiatrique de la ligne médiane
Fuchs, Q. (2022) · theses.fr (ABES) · doi:10.70675/be0bde8bzaab7z4b1fz8704zbcdc0c236054
Lee, C., Byeon, Y., Kim, K., Lee, W., Hwang, K., Dho, Y., Sung, K. S., Roh, T. H., Chong, K., Park, K., et al. (2026) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2026.0009
Metadata
- Authors
- Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E.
- Affiliations
- Atrium Health Wake Forest Baptist (US)
- Mayo Clinic (US)
- Brain Tumor Center of Excellence Wake Forest Comprehensive Cancer Center Winston-Salem NC 27157 USA
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2018-08-09
- Volume
- 10
- Issue
- 18
- Pages
- 2227-2236
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- PMC
- PMC6479274
- OpenAlex
- W2886561153
- Cited by
- 40
- References
- 85
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 1 · 2018: 1
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Medicinal Chemistry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA012197)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-2α, glioblastoma, glioma stem cells, tumor hypoxia, PT2385, targeted cancer therapy, drug resistance
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Glioma, Humans, Indans, Sulfones, RNA Interference, RNA, Small Interfering, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.